Pyxis Q3 Loss Narrows to $20.0M; Cash Runway Extended Into 1H 2028
PYXS sits 60% above its 52-week low of $1.03.
Summary
Pyxis reported a narrower $20.0M Q3 loss and said cash plus October offering proceeds fund operations into the first half of 2028, covering the planned mid-2027 launch of its Phase 3 head and neck cancer trial.
Key Events · Earnings and Guidance · PYXS
-
Q3 Loss Narrows to $20.0M
Net loss was $20.0M, or $0.24 per share, versus $22.0M, or $0.35 per share, a year earlier; R&D fell to $16.6M from $17.8M on lower manufacturing costs.
-
Runway Extended Into 1H 2028
Cash, restricted cash and short-term investments totaled $57.0M at September 30, 2026; with net October offering proceeds, the company says it can fund operations into the first half of 2028.
-
Phase 3 Trial Set for Mid-2027
The global Headliner SM trial will randomize approximately 500 patients 1:1 to MICVO or investigator's choice of cetuximab, docetaxel or methotrexate, with co-primary endpoints of overall response rate and overall survival.
-
FDA Dose Feedback Due Q1 2027
FDA feedback on dose selection following the End-of-Phase 2 meeting is expected in the first quarter of 2027; updated monotherapy overall survival data is expected in the first half of 2027.
Analysis · PYXS · Life Sciences
The quarter itself was unremarkable: R&D fell to $16.6M from $17.8M and G&A dropped to $4.0M, cutting the net loss to $20.0M from $22.0M a year ago. What matters is the runway. With $57.0M of cash and securities at September 30 plus net proceeds from the October offering, operations are funded into the first half of 2028, past the planned mid-2027 start of the Phase 3 Headliner SM trial. The company also laid out a concrete regulatory path: FDA dose-selection feedback in Q1 2027, roughly 500 patients randomized 1:1 against investigator's choice of cetuximab, docetaxel or methotrexate, and co-primary endpoints of overall response rate and overall survival. Updated overall survival data from the monotherapy study is expected in the first half of 2027, and a December 2026 update will carry the first combination data with pembrolizumab in first-line disease.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PYXS was trading at $1.65 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $198.5M. The 52-week trading range was $1.03 to $5.55. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.